Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.29 USD | +4.88% | +7.95% | +53.85% |
Kurzporträt
Mitarbeiterzahl: 93
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Paula Ragan
FOU | Founder | 54 | 01.01.10 |
Adam Mostafa
DFI | Director of Finance/CFO | 44 | 01.09.18 |
Mary DiBiase
COO | Chief Operating Officer | 63 | 01.01.17 |
Chief Tech/Sci/R&D Officer | - | 01.08.23 | |
Art Taveras
CTO | Chief Tech/Sci/R&D Officer | 60 | 02.11.20 |
Murray Stewart
BRD | Director/Board Member | 63 | 29.03.19 |
Brian Bowersox
PRN | Corporate Officer/Principal | - | - |
Mark Baldry
PRN | Corporate Officer/Principal | - | 26.10.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 01.07.18 |
David McGirr
BRD | Director/Board Member | 69 | 01.09.17 |
Paula Ragan
FOU | Founder | 54 | 01.01.10 |
Gary Bridger
BRD | Director/Board Member | 61 | 01.10.18 |
Alison Lawton
BRD | Director/Board Member | 62 | 05.10.20 |
Bill Aliski
BRD | Director/Board Member | 75 | 18.09.19 |
Director/Board Member | 62 | 14.10.21 | |
Murray Stewart
BRD | Director/Board Member | 63 | 29.03.19 |
R. Woods
BRD | Director/Board Member | 57 | 16.10.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 167 937 781 | 162 995 043 ( 97,06 %) | 0 | 97,06 % |
Unternehmenskontakt
X4 Pharmaceuticals, Inc.
61 North Beacon Street 4th floor
02134, Boston
+857 529 8300
http://www.x4pharma.comSektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+53.85% | 217 Mio. | |
+4.09% | 43.84 Mrd. | |
+47.24% | 41.25 Mrd. | |
+9.45% | 41.68 Mrd. | |
-10.92% | 27.04 Mrd. | |
+9.32% | 25.53 Mrd. | |
-24.87% | 18.18 Mrd. | |
+29.70% | 12.29 Mrd. | |
+1.28% | 12.29 Mrd. | |
+7.78% | 11.15 Mrd. |
- Börse
- Aktien
- A2PFVY Aktie
- Unternehmen X4 Pharmaceuticals, Inc.